Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Viral Recombination00:57

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Recombinant DNA01:09

Recombinant DNA

Overview
Cross-reactivity00:42

Cross-reactivity

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Comparison of candidate vaccines against Tick-borne encephalitis based on mRNA, simian adenovirus serotype 25 and a chimeric replication-competent yellow fever vaccine strain].

Voprosy virusologii·2026
Same author

[Influenza virus infection affects the efficacy of the treatment of dyslipidemia in mice with a polyisoprenoid-based drug].

Voprosy virusologii·2026
Same author

Genetic characteristics of the isolate of human adenovirus type 55 (<i>Adenoviridae: Mastadenovirus</i>) isolated in Moscow in 2022.

Voprosy virusologii·2025
Same author

[Characteristics of the epidemic process of measles, rubella and mumps in Moscow and assessment of their seroprevalence at the present stage].

Voprosy virusologii·2025
Same author

The Parameters of Long-Term Humoral Immunity Induced by a Single Injection of the Sputnik Light Vaccine Among Noninfected Volunteers and Those Infected with SARS-CoV-2.

Acta naturae·2025
Same author

Straightforward MALDI-TOF MS based screening approach for selection of recombinant protein-expressing <i>E. coli</i>.

Biotechnology notes (Amsterdam, Netherlands)·2025

Related Experiment Video

Updated: May 14, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

Recombinant influenza vaccines.

E S Sedova1, D N Shcherbinin, A I Migunov

  • 1Gamaleya Research Institute of Epidemiology and Microbiology, Gamaleya Str., 18, Moscow, Russia, 123098.

Acta Naturae
|January 25, 2013
PubMed
Summary
This summary is machine-generated.

This review explores challenges in recombinant influenza vaccine production, highlighting adenoviral vectors as a promising platform for developing cross-protective vaccines. These vectors facilitate antigen preservation and immune response induction for improved influenza vaccine strategies.

Keywords:
Recombinant vaccineimmunizationinfluenza

More Related Videos

Generation of Recombinant Influenza Virus from Plasmid DNA
11:31

Generation of Recombinant Influenza Virus from Plasmid DNA

Published on: August 3, 2010

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
12:18

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

Related Experiment Videos

Last Updated: May 14, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

Generation of Recombinant Influenza Virus from Plasmid DNA
11:31

Generation of Recombinant Influenza Virus from Plasmid DNA

Published on: August 3, 2010

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
12:18

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

Area of Science:

  • Vaccinology
  • Molecular Biology
  • Immunology

Background:

  • Traditional influenza vaccine production faces challenges.
  • Recombinant vaccine technologies offer potential solutions.
  • Developing cross-protective vaccines remains a key goal.

Purpose of the Study:

  • To review problems in recombinant influenza vaccine construction and production.
  • To investigate novel approaches for influenza vaccine development.
  • To assess the practicability of adenoviral vector-based vaccines.

Main Methods:

  • Review of current literature on recombinant influenza vaccine technologies.
  • Analysis of reverse genetics, virus-like particles, and DNA/viral vector-based vaccines.
  • Focus on adenoviral vectors for gene delivery and antigen expression.

Main Results:

  • Recombinant approaches, including viral vectors, can preserve native antigen structure.
  • Adenoviral vectors demonstrate potential for efficient gene delivery and mucosal penetration.
  • Adenoviral vectors can induce long-term antigen persistence and innate immune responses.

Conclusions:

  • Adenoviral vectors are a promising platform for novel recombinant influenza vaccines.
  • Expression of hemagglutinin genes from various strains on adenoviral vectors is feasible.
  • This approach may lead to the development of effective cross-protective influenza vaccines.